Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection
Top Cited Papers
- 15 April 2014
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 189 (8), 975-982
- https://doi.org/10.1164/rccm.201312-2208oc
Abstract
Rationale: Chronic infection with Pseudomonas aeruginosa is associated with an increased exacerbation frequency, a more rapid decline in lung function, and increased mortality in patients with bronchiectasis. Objectives: To perform a randomized placebo-controlled study assessing the efficacy and safety of inhaled colistin in patients with bronchiectasis and chronic P. aeruginosa infection. Methods: Patients with bronchiectasis and chronic P. aeruginosa infection were enrolled within 21 days of completing a course of antipseudomonal antibiotics for an exacerbation. Participants were randomized to receive colistin (1 million IU; n = 73) or placebo (0.45% saline; n = 71) via the I-neb twice a day, for up to 6 months. Measurements and Main Results: The primary endpoint was time to exacerbation. Secondary endpoints included time to exacerbation based on adherence recorded by the I-neb, P. aeruginosa bacterial density, quality of life, and safety parameters. All analyses were on the intention-to-treat population. Median time (25% quartile) to exacerbation was 165 (42) versus 111 (52) days in the colistin and placebo groups, respectively (P = 0.11). In adherent patients (adherence quartiles 2–4), the median time to exacerbation was 168 (65) versus 103 (37) days in the colistin and placebo groups, respectively (P = 0.038). P. aeruginosa density was reduced after 4 (P = 0.001) and 12 weeks (P = 0.008) and the St. George’s Respiratory Questionnaire total score was improved after 26 weeks (P = 0.006) in the colistin versus placebo patients, respectively. There were no safety concerns. Conclusions: Although the primary endpoint was not reached, this study shows that inhaled colistin is a safe and effective treatment in adherent patients with bronchiectasis and chronic P. aeruginosa infection. Clinical trial registered with http://www.isrctn.org/ (ISRCTN49790596)Keywords
This publication has 31 references indexed in Scilit:
- Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised studyEuropean Respiratory Journal, 2012
- Immunity and bacterial colonisation in bronchiectasisThorax, 2011
- British Thoracic Society guideline for non-CFbronchiectasisThorax, 2010
- The Adaptive Aerosol Delivery (AAD) Technology: Past, Present, and FutureJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary ReportJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Mortality in bronchiectasis: a long-term study assessing the factors influencing survivalEuropean Respiratory Journal, 2009
- Microbiologic follow-up study in adult bronchiectasisRespiratory Medicine, 2007
- Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factorsThorax, 2002
- Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic FibrosisThe Journal of Infectious Diseases, 1999
- Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic studyThorax, 1997